Biotech Values

[willyw]

is fantastic for the Patient, but not so for the Producer.

Ha!! Tell that to John Martin.

Look at what Gilead spent on Pharmasett (11 billion for a drug in Phase 3) and what they will net after a decade of treatments.
There may be a small silver lining for Gilead in this tragedy.

Look at what happened to Incivek; they had about 2 years before warehousing started. I think Gilead will have an extended period of income. China hasn't really even started yet. The prospects for Abbvie and G/P still look good to me as well.